PKC412--a protein kinase inhibitor with a broad therapeutic potential.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Anti-Cancer Drug Design

• Publication date

  2000-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 10888033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

  1999cited by this paper
• Multiple signals converging on NF-kappaB.

  1999cited by this paper
• Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

  1999cited by this paper
• Signalling through phosphoinositide 3-kinases: the lipids take centre stage.

  1999cited by this paper
• Interactions between mitogenic stimuli, or, a thousand and one connections.

  1999cited by this paper
• Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.

  1999cited by this paper
• [PKC 412].

  1999cited by this paper
• Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.

  1999cited by this paper
• Epidermal growth factor receptors: critical mediators of multiple receptor pathways.

  1999cited by this paper
• Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

  1999cited by this paper
• The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.

  1999cited by this paper
• Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.

  1998cited by this paper
• Vascular endothelial growth factor is essential for corpus luteum angiogenesis

  1998cited by this paper
• Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development.

  1998cited by this paper
• Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.

  1998cited by this paper
• Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700

  1998cited by this paper
• Protein kinase C activation and the development of diabetic complications.

  1998cited by this paper
• Signaling angiogenesis and lymphangiogenesis.

  1998cited by this paper
• Mechanisms and consequences of activation of protein kinase B/Akt.

  1998cited by this paper
• Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.

  1998cited by this paper
• Protein tyrosine phosphatases in signal transduction.

  1997cited by this paper
• Mechanisms of angiogenesis

  1997cited by this paper
• Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.

  1997cited by this paper
• How receptors talk to trimeric G proteins.

  1997cited by this paper
• Mitogen-activated protein kinase pathways.

  1997cited by this paper
• The biology of vascular endothelial growth factor.

  1997cited by this paper
• Essential role of growth hormone in ischemia-induced retinal neovascularization.

  1997cited by this paper
• Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents.

  1997cited by this paper
• Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.

  1997cited by this paper
• Targeting signal transduction for disease therapy.

  1996cited by this paper
• Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.

  1996cited by this paper
• Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.

  1996cited by this paper
• Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.

  1996cited by this paper
• Ras effectors.

  1996cited by this paper
• Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.

  1996cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Decreased potency of MDR‐modulators under serum conditions determined by a functional assay

  1995cited by this paper
• Comparative Analysis of Vascular Endothelial Growth Factor Receptors on Retinal and Aortic Vascular Endothelial Cells

  1995cited by this paper
• Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines

  1995cited by this paper
• Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

  1995cited by this paper
• P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.

  1995cited by this paper
• The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.

  1995cited by this paper
• Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.

  1995cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha.

  1994cited by this paper
• Protein kinase C--a question of specificity.

  1994cited by this paper
• Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression.

  1994cited by this paper
• Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

  1994cited by this paper
• Regulation of protein kinase C and role in cancer biology

  1994cited by this paper
• Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

  1994cited by this paper
• The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance

  1994cited by this paper
• Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance.

  1993cited by this paper
• Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.

  1993cited by this paper
• Second International Symposium on Cytostatic Drug Resistance.

  1993cited by this paper
• High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

  1993cited by this paper
• Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo.

  1993cited by this paper
• How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.

  1993cited by this paper
• Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells.

  1993cited by this paper
• Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha.

  1993cited by this paper
• The pathway to signal achievement

  1993cited by this paper
• Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.

  1993cited by this paper
• Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.

  1992cited by this paper
• Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation.

  1992cited by this paper
• Protein kinase C, calcium and phospholipid degradation.

  1992cited by this paper
• Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a

  1991cited by this paper
• Identification of a new endothelial cell growth factor receptor tyrosine kinase.

  1991cited by this paper
• Multidrug resistance.

  1991cited by this paper
• 'Crosstalk': a pivotal role for protein kinase C in modulating relationships between signal transduction pathways.

  1991cited by this paper
• A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.

  1991cited by this paper
• Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells.

  1990cited by this paper
• Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.

  1990cited by this paper
• A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity

  1989cited by this paper

• Recent advances in PKC inhibitor development: Structural design strategies and therapeutic applications.

  2025cites this paper
• Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin

  2025cites this paper
• Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment

  2024cites this paper
• Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges.

  2024cites this paper
• Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.

  2023cites this paper
• Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response

  2023cites this paper
• An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases

  2023cites this paper
• Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening

  2023influential citation
• Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia

  2023cites this paper
• Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level

  2023cites this paper
• Cell-based screen identifies porphyrins as FGFR3 activity inhibitors with therapeutic potential for achondroplasia and cancer

  2023cites this paper
• Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

  2023cites this paper
• Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

  2022cites this paper
• Target Therapies for Systemic Mastocytosis: An Update

  2022cites this paper
• FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

  2022cites this paper
• Midostaurin

  2022cites this paper
• Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

  2021cites this paper
• Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway

  2021cites this paper
• Putative role of natural products as Protein Kinase C modulator in different disease conditions

  2021cites this paper
• Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

  2021cites this paper
• Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma

  2020cites this paper
• Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism

  2020cites this paper
• New Seco-DSP derivatives as potent chemosensitizers.

  2020cites this paper
• Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer

  2020cites this paper
• Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date

  2020cites this paper
• Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

  2020cites this paper
• Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism

  2020cites this paper
• Hypomorph Mutation-Directed Small-Molecule Protein-Protein Interaction Inducers to Restore Mutant SMAD4-Suppressed TGF-β Signaling.

  2020cites this paper
• Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness

  2020cites this paper
• Recent advances in FLT3 inhibitors for acute myeloid leukemia.

  2020cites this paper
• Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

  2020cites this paper
• CMAR_A_196568 151..163

  2020cites this paper
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

  2020cites this paper
• CMAR_A_177894 8817..8828

  2019cites this paper
• Small molecule amyloid-beta protein precursor processing modulators lower amyloid-beta peptide levels via cKit signaling

  2019influential citation
• The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

  2019cites this paper
• ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT.

  2019cites this paper
• Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.

  2019cites this paper
• Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens

  2019cites this paper
• Small Molecule Amyloid-β Protein Precursor Processing Modulators Lower Amyloid-β Peptide Levels via cKit Signaling

  2019cites this paper
• Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

  2019cites this paper
• Revisiting NTRKs as an emerging oncogene in hematological malignancies

  2019cites this paper
• Mast Cell Disorders and Anaphylaxis

  2019cites this paper
• Small molecules effective for disruption of HIV-1 latency

  2019cites this paper
• Overcoming the Protective Effect of the Bone Marrow Microenvironment by Dual FLT3 and BET Inhibition in FLT3-ITD Acute Myeloid Leukemia

  2019cites this paper
• KIT as a therapeutic target for non‐oncological diseases

  2019cites this paper
• The transcription factor STAT5 catalyzes Mannich ligation reactions yielding inhibitors of leukemic cell proliferation

  2019cites this paper
• Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.

  2019cites this paper
• Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

  2019cites this paper
• A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.

  2019cites this paper
• FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist

  2018cites this paper
• Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

  2018cites this paper
• The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

  2018cites this paper
• Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

  2018cites this paper
• Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin

  2018cites this paper
• Kit Mutations: New Insights and Diagnostic Value.

  2018cites this paper
• Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.

  2018cites this paper
• Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells*

  2018influential citation
• Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

  2017cites this paper
• Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

  2017cites this paper
• Midostaurin inhibits hormone-refractory prostate cancer PC-3 cells by modulating nPKCs and AP-1 transcription factors and their target genes involved in cell cycle

  2017cites this paper
• Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.

  2017cites this paper
• Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation

  2017cites this paper
• Midostaurin for the treatment of acute myeloid leukemia.

  2017cites this paper
• Title : Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK 3 β

  2017cites this paper
• Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

  2017cites this paper
• Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis

  2017cites this paper
• Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia

  2017cites this paper
• Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis

  2017cites this paper
• Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells

  2017influential citation
• Midostaurin: A New Oral Agent Targeting FMS‐Like Tyrosine Kinase 3‐Mutant Acute Myeloid Leukemia

  2017cites this paper
• Targeted Treatment Options in Mastocytosis

  2017cites this paper
• Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β

  2017cites this paper
• Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

  2017cites this paper
• Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

  2017cites this paper
• The Development Of Chemical Methods To Discover Kinase Substrates And Map Cell Signaling With Gamma-Modified Atp Analog-Dependent Kinase-Catalyzed Phosphorylation

  2017cites this paper
• Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia

  2017influential citation
• A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.

  2017cites this paper
• Selecting initial treatment of acute myeloid leukaemia in older adults.

  2017cites this paper
• Midostaurin: a magic bullet that blocks mast cell expansion and activation

  2017cites this paper
• Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

  2016cites this paper
• Advanced Screening and Integrative Analysis for Biotechnology and Disease

  2016cites this paper
• FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.

  2016cites this paper
• Activation of HIV-1 expression in latently infected CD4+ T cells by the small molecule PKC412

  2016cites this paper
• Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy

  2016cites this paper
• Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

  2016cites this paper
• Midostaurin: an emerging treatment for acute myeloid leukemia patients

  2016influential citation
• Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer

  2016cites this paper
• Identification of Bromodomain-Containing Protein 4 (BRD4) as a Novel Marker and Epigenetic Target in Systemic Mastocytosis and Mast Cell Leukemia

  2016cites this paper
• Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells

  2015cites this paper
• The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2′-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells*

  2015cites this paper
• Systemic Mastocytosis: Clinical Update and Future Directions.

  2015cites this paper
• Current treatment options in patients with mastocytosis: status in 2015 and future perspectives

  2015cites this paper
• Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers

  2015cites this paper
• The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.

  2015cites this paper
• Development of Midostaurin as a Tyrosine Kinase Inhibitor

  2015cites this paper
• Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

  2015cites this paper
• Tribbles pseudokinases: novel targets for chemical biology and drug discovery?

  2015cites this paper
• Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

  2014cites this paper
• Equilibrium gel filtration to measure plasma protein binding of very highly bound drugs.

  2014cites this paper